EPISODE · May 5, 2026 · 1 MIN
Pfizer Crushes Q1, Eyes Long-Term Growth
from The Daily News Now! Business
Pfizers Q1 earnings surpass expectations, with adjusted EPS at $0.75 and revenue at $14.45B. Newer launches and acquisitions drive growth, offsetting Covid product decline. Pfizer invests heavily in pipeline, eyeing long-term gains like the $10B Metsera acquisition. Key trial data drops, including lung cancer drug results, position Pfizer for post-pandemic success. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1b2d16db99f32b04
NOW PLAYING
Pfizer Crushes Q1, Eyes Long-Term Growth
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m